Announcement no. 21
Managers’ transactions
1. Details of the person discharging managerial responsibilities/person closely associated | |
a) | |
2. Reason for the notification | |
a) Position/status | Closely associated person to |
b) Initial notification/amendment | Initial notification |
3. Details of the issuer | |
a) | |
b) LEI | 5299004SWFL5JAN4W830 |
4. Details of the transaction(s) | |
a) Description of the financial instrument type of instrument and Identification code | Shares, ISIN code DK0011048619 |
b) Nature of the transaction | Sales of shares |
c) Price(s) and volume(s) | Price: DKK 3.2011 per share, Volume: 246,224 |
d) Aggregated information - Aggregated volume - Aggregated price | N/A |
e) Date of the transaction | |
f) Place of the transaction |
For inquiries, please contact
EU Investor Relations
P: +45 4529 0000
E: investor@bioporto.com
US Investor Relations
P: +1 617 430 7577
E: arr@lifesciadvisors.com
About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/
About
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
Attachment
- 2023 12 09 - Announcement no. 21
© OMX, source